• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.

作者信息

Wästerlid T, Biccler J L, Brown P N, Bøgsted M, Enblad G, Mészáros Jørgensen J, Christensen J H, Wahlin B E, Smedby K E, El-Galaly T C, Jerkeman M

机构信息

Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden.

Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

出版信息

Ann Oncol. 2018 Aug 1;29(8):1882-1883. doi: 10.1093/annonc/mdy184.

DOI:10.1093/annonc/mdy184
PMID:29790897
Abstract
摘要

相似文献

1
Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.对于弥漫性大B细胞淋巴瘤的治疗，6个周期的R-CHOP-21方案并不逊于8个周期：一项北欧淋巴瘤组基于人群的研究。
Ann Oncol. 2018 Aug 1;29(8):1882-1883. doi: 10.1093/annonc/mdy184.
2
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗新诊断弥漫性大 B 细胞非霍奇金淋巴瘤患者：14 天与 21 天周期强化剂量的 3 期比较。
Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.
3
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.利妥昔单抗密集化疗联合或不联合大剂量化疗和自体干细胞移植治疗高危弥漫性大 B 细胞淋巴瘤（DLCL04）：一项多中心、开放标签、随机、对照、3 期研究的最终结果。
Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
4
Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.弥漫性大 B 细胞淋巴瘤中 R-CHOP-14 与 R-CHOP-21 的疗效相当——来自前瞻性德国肿瘤登记处淋巴肿瘤学研究的数据。
Eur J Haematol. 2019 Nov;103(5):460-471. doi: 10.1111/ejh.13295. Epub 2019 Sep 4.
5
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.ACVBP 强化化疗联合利妥昔单抗对比标准 CHOP 联合利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤（LNH03-2B）：一项开放标签、随机、3 期临床试验。
Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4.
6
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.R-CHOP 化疗治疗弥漫性大 B 细胞淋巴瘤患者中巩固性放疗的获益。
J Clin Oncol. 2010 Sep 20;28(27):4170-6. doi: 10.1200/JCO.2009.27.3441. Epub 2010 Aug 16.
7
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.与标准利妥昔单抗 CHOP 相比，密集剂量利妥昔单抗 CHOP 治疗老年弥漫性大 B 细胞淋巴瘤患者（LNH03-6B 研究）：一项随机 3 期试验。
Lancet Oncol. 2013 May;14(6):525-33. doi: 10.1016/S1470-2045(13)70122-0. Epub 2013 Apr 9.
8
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.依维莫司联合R-CHOP-21方案治疗初治弥漫性大B细胞淋巴瘤（NCCTG 1085 [联盟]）：1期安全性、有效性及可行性试验结果
Lancet Haematol. 2016 Jul;3(7):e309-16. doi: 10.1016/S2352-3026(16)30040-0. Epub 2016 Jun 5.
9
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.中国弥漫大 B 细胞淋巴瘤初治患者中密集型利妥昔单抗联合 CHOP 方案与标准利妥昔单抗联合 CHOP 方案的随机、多中心、开放性 3 期临床试验。
Cancer Res Treat. 2019 Jul;51(3):919-932. doi: 10.4143/crt.2018.230. Epub 2018 Oct 2.
10
Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱及泼尼松方案（R-CHOP）中长春新碱剂量减少对弥漫性大B细胞淋巴瘤预后的影响
Ann Hematol. 2016 Jan;95(1):41-47. doi: 10.1007/s00277-015-2514-9. Epub 2015 Oct 5.

引用本文的文献

1
Unusual symptoms reveal a rare splenic lymphoma: a case report of PS-DLBCL with neck and shoulder pain as the initial presentation.罕见症状揭示罕见脾淋巴瘤：以颈部和肩部疼痛为首发表现的原发性皮肤弥漫大B细胞淋巴瘤病例报告
Front Oncol. 2025 Feb 4;15:1449966. doi: 10.3389/fonc.2025.1449966. eCollection 2025.
2
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma.6xR-CHOP21 与 6xR-CHOP21+2R 方案治疗晚期弥漫性大 B 细胞淋巴瘤患者的疗效比较。
Blood Cancer J. 2024 Sep 12;14(1):157. doi: 10.1038/s41408-024-01137-0.
3
[Chinese expert consensus on the diagnosis and management of elderly patients with diffuse large B-cell lymphoma (2024)].
《老年弥漫性大B细胞淋巴瘤诊断与治疗中国专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):322-329. doi: 10.3760/cma.j.cn121090-20231228-00343.
4
The Relative Dose Intensity Changes during Cycles of Standard Regimens in Patients with Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤患者标准方案治疗周期中的相对剂量强度变化
Cancers (Basel). 2023 Sep 7;15(18):4458. doi: 10.3390/cancers15184458.
5
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options.弥漫性大B细胞淋巴瘤（DLBCL）：患者早期管理及新出现的治疗选择
Onco Targets Ther. 2022 Dec 6;15:1481-1501. doi: 10.2147/OTT.S326632. eCollection 2022.
6
How I treat older patients with DLBCL in the frontline setting.我在一线治疗老年弥漫性大 B 细胞淋巴瘤患者的方法。
Blood. 2023 May 25;141(21):2566-2575. doi: 10.1182/blood.2020008239.
7
A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China.一项针对中国239例70岁以上弥漫性大B细胞淋巴瘤患者的多中心研究。
Front Pharmacol. 2022 Jul 18;13:953808. doi: 10.3389/fphar.2022.953808. eCollection 2022.
8
DLBCL 1L-What to Expect beyond R-CHOP?弥漫性大B细胞淋巴瘤1线治疗——R-CHOP方案之外还有什么可期待的？
Cancers (Basel). 2022 Mar 11;14(6):1453. doi: 10.3390/cancers14061453.
9
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.采用 EPOCH 化疗联合利妥昔单抗的应答适应性治疗方案治疗 HIV 相关的 B 细胞非霍奇金淋巴瘤。
Haematologica. 2021 Mar 1;106(3):730-735. doi: 10.3324/haematol.2019.243386.